TRANCE/TNFSF11/RANK L Antibody (70525) [Unconjugated]

In the presence of Recombinant Mouse M‑CSF (20 ng/mL, Catalog # 416-ML), Recombinant Human TRANCE/TNFSF11/RANK L (Catalog # 390-TN) induces osteoclast-like cell formation in RAW 264.7 mouse macrophages in a dose-dependent manner (orange line), as measured by TRAP (tartrate-resistant acid phosphatase) activity in cell lysates. Under these conditions, osteoclast-like cell formation elicited by Recombinant Human TRANCE/TNFSF11/RANK L (30 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human TRANCE/TNFSF11/RANK L Monoclonal Antibody (Catalog # MAB626). The ND50 is typically 0.8-2.5 µg/mL.

TRANCE/TNFSF11/RANK L was detected in immersion fixed paraffin-embedded sections of human lymph node using 5 µg/mL Mouse Anti-Human TRANCE/TNFSF11/RANK L Monoclonal Antibody (Catalog # MAB626) overnight at 4 °C. Tissue was stained with the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

• Reactivity: Hu
• Applications: IHC, B/N
• Clone: 70525
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

TRANCE/TNFSF11/RANK L Antibody (70525) [Unconjugated] Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human TRANCE/TNFSF11/RANK L
  Gly136-Asp317 (Ala194Gly)
  Accession # O14788
• Specificity: Detects human TRANCE/TNFSF11/RANK L in direct ELISAs. No cross-reactivity with recombinant mouse TRANCE is observed.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Gene: TNFSF11
• Purity Statement: Protein A or G purified from ascites
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 8-25 ug/mL
  • Neutralization 0.8-2.5 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TRANCE/TNFSF11/RANK L Antibody (70525) [Unconjugated]

• CD254 antigen
• CD254
• ODF
• OPGL
• OPGLOPTB2
• Osteoclast differentiation factor
• Osteoprotegerin ligand
• RANK L
• RANKL
• RANKLreceptor activator of nuclear factor kappa B ligand
• Receptor activator of nuclear factor kappa-B ligand
• sOdf
• TNF-related activation-induced cytokine
• TNFSF11
• TRANCE
• TRANCEODFhRANKL2
• tumor necrosis factor (ligand) superfamily, member 11
• tumor necrosis factor ligand superfamily member 11

Background

TNF-related activation-induced cytokine (TRANCE; also RANKL, OPGL, and ODF) is a 35 kDa (predicted) type II transmembrane glycoprotein and member of the TNF cytokine family. Human TRANCE is 317 amino acids (aa) in length and contains a 47 aa cytoplasmic region, a 21 aa transmembrane region, and a 249 extracellular domain (ECD), which contains two potential sites of N-linked glycosylation. Splicing variants produce three isoforms for human TRANCE. Isoform 1 is the standard form. In isoform 2 lacks aa 1-73, and isoform 3 lacks aa 1-47. TRANCE is expressed highest in the peripheral lymph nodes and weaker in the spleen, peripheral blood leukocytes, bone marrow, heart,placenta, skeletal muscle, stomach, and thyroid. TRANCE plays a role in osteoclast differentiation and activation.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for TRANCE/TNFSF11/RANK L Antibody (MAB626)(12)

Publications using MAB626

• Valeria Fernández Vallone, Francisco Raúl Borzone, Leandro Marcelo Martinez, María Belén Giorello, Hosoon Choi, Federico Dimase et al. Spontaneous Osteoclastogenesis, a risk factor for bone metastasis in advanced luminal A-type breast cancer patients Frontiers in Oncology 2/20/2023 [PMID: 36890825]
• I Gomes, BP de Almeida, S Dâmaso, A Mansinho, I Correia, S Henriques, R Cruz-Duart, G Vilhais, P Félix, P Alves, P Corredeira, NL Barbosa-Mo, L Costa, S Casimiro Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer Oncotarget, 2020-05-12;11(19):1714-1728. 2020-05-12 [PMID: 32477461] (Neutralization, Human)
• CGJ Moonen, TJ de Vries, P Rijkschroe, PE Poubelle, EA Nicu, BG Loos The Possible Role of Neutrophils in the Induction of Osteoclastogenesis J Immunol Res, 2019-09-15;2019(0):8672604. 2019-09-15 [PMID: 31637266] (ICC, Human)
• Ferguson J, Wilcock DJ, McEntegart S et al. Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival Pigment Cell Melanoma Res 7/19/2019 [PMID: 31323160]
• Kim H, Kim K, Kim B, Cho M, Lee S The effect of vascular endothelial growth factor on osteoclastogenesis in rheumatoid arthritis. PLoS ONE, 2015-04-20;10(4):e0124909. 2015-04-20 [PMID: 25894998] (IHC, Human)
• Harunori Takeshita, Masayasu Kitano, Tsuyoshi Iwasaki, Sachie Kitano, Sachi Tsunemi, Chieri Sato et al. Sphingosine 1-phosphate (S1P)/S1P receptor 1 signaling regulates receptor activator of NF-kappa B ligand (RANKL) expression in rheumatoid arthritis Biochemical and Biophysical Research Communications 3/9/2012 [PMID: 22326262]
• Amiable N, Tat SK, Lajeunesse D, Duval N, Pelletier JP, Martel-Pelletier J, Boileau C Proteinase-activated receptor (PAR)-2 activation impacts bone resorptive properties of human osteoarthritic subchondral bone osteoblasts. Bone, 2009-03-02;44(6):1143-50. 2009-03-02 [PMID: 19264156] (Flow Cytometry, Human)
• Gendron S, Boisvert M, Chetoui N, Aoudjit F alpha1beta1 integrin and interleukin-7 receptor up-regulate the expression of RANKL in human T cells and enhance their osteoclastogenic function. Immunology, 2008-05-13;125(0):359. 2008-05-13 [PMID: 18479350] (Western Blot, Human)
• Lee N, Smolarz AJ, Olson S, David O, Reiser J, Kutner R, Daw NC, Prockop DJ, Horwitz EM, Gregory CA A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br. J. Cancer, 2007-11-06;97(11):1552-9. 2007-11-06 [PMID: 17987039] (IHC-P, Western Blot, Human)
• Makrygiannakis D, af Klint E, Catrina SB, Botusan IR, Klareskog E, Klareskog L, Ulfgren AK, Catrina AI Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis. Arthritis Rheum., 2006-05-01;54(5):1463-72. 2006-05-01 [PMID: 16646024] (Flow Cytometry, IHC, Western Blot, Human)
• Fonseca JE, Cortez-Dias N, Francisco A, Sobral M, Canhao H, Resende C, Castelao W, Macieira C, Sequeira G, Saraiva F, da Silva JA, Carmo-Fonseca M, Viana Queiroz M Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome. Clin. Exp. Rheumatol., 2005-03-01;23(2):185-92. 2005-03-01 [PMID: 15895888] (IHC, Human)
• Mandelin J, Li TF, Hukkanen M, Liljestrom M, Salo J, Santavirta S, Konttinen YT Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. J. Rheumatol., 2005-04-01;32(4):713-20. 2005-04-01 [PMID: 15801030] (IHC, Human)

Bioinformatics

• Gene Symbol: TNFSF11
• Uniprot:
  • O14788()